The Health Resources and Services Administration should increase its oversight of private nonprofit hospitals that participate in the 340B drug savings program to ensure they meet eligibility requirements, the Government Accountability Office said in a report released today. Specifically, GAO said HRSA should ensure that it uses reliable information to verify nonprofit status for all nongovernmental hospitals in the program, verify that each of these hospitals has a contract with a state or local government as required, and verify that the contract was in effect prior to the beginning of the audit review period. GAO also recommended that HRSA revise its contract audit procedures and provide auditors with more specific guidance on how to determine whether the contracts require the hospitals to serve low-income individuals not eligible for Medicaid or Medicare. In comments in the report, the Department of Health and Human Services concurred with all of the recommendations except the one to verify that all nongovernmental hospitals have the required contract with a state or local government.
 
AHA Executive Vice President Tom Nickels said, “We look forward to reviewing this report closely. Most important is that tax-exempt hospitals are accountable to the government and their communities in a variety of important ways. For example, they publicly report annually the benefits they provide. In the most recent year for which comprehensive data is available, 340B tax-exempt hospitals provided more than $56 billion in total benefits to their communities.”

Headline
The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party…
Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…
Headline
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B…
Headline
The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program because “a rebate mechanism of any kind…
Headline
The AHA and others April 17 filed an amicus brief requesting the U.S. Court of Appeals for the 4th Circuit grant en banc review of a panel decision that…
Headline
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…